– Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer –  – First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 – – Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia – – Announced Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Injury Repair – – U.S. Department of Defense funding for procurement of bioengineered blood vessels – – Major milestone upcoming: Top-line interim results from V012 Phase 3 study in hemodialysis access – -Conference call today at 8:00 am ET – DURHAM, N.C., May 13, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc....

Forecasting Sequential Quarter Over Quarter Revenue and Margin Growth Throughout the Year with Second Quarter 2026 at a Company Record of $455 Million MIGDAL HAEMEK, Israel, May 13, 2026 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ/TASE: TSEM) reports today its results for the first quarter ended March 31, 2026. First Quarter of 2026 Results OverviewRevenue for the first quarter of 2026 was $414 million as compared to $358 million for the first quarter of 2025, representing 15% year-over-year revenue growth. Gross profit and operating profit for the first quarter of 2026 were $111 million and $65 million, respectively, compared to $73 million and $33 million in the first quarter of 2025, respectively, representing 52% gross profit growth and 96% operating profit growth. Net profit for the first quarter of 2026 was $65 million,...

Management will host an earnings webcast on Wednesday, May 13 at 8:30 a.m. ET TOKYO, May 13, 2026 (GLOBE NEWSWIRE) — CTW (Nasdaq: CTW) (“the Company”), a leading game platform company providing global access to web-based games through its flagship HTML5 platform, G123.jp, reports financial results for the six months ending January 31, 2026 (“1H26”), highlighting the resilience of its asset-light operating model, which drove significant improvement in segment profitability and Adjusted EBITDA despite modest year-over-year revenue softness. 1H26 Financial and Business HighlightsRevenue of $40.9 million in 1H26, a decline of 1% from $41.2 million in the six months ended January 31, 2025 (“1H25”)Segment profit increased 55% year-over-year and Adjusted EBITDA increased 16% year-over-year, demonstrating the flexibility of CTW’s asset-light...

– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 initiations in both indications expected in Q1 2027 – – Phase 2 VENTURE trial in COPD ongoing; Company to cap further enrollment; data now expected in the second half of 2027 – – Upcoming data presentations at ATS and EAACI to further elaborate the clinical profile of verekitug – WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the first quarter ended March 31, 2026, and highlighted its continued progress in developing verekitug...

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline. “Plinabulin continues to demonstrate the ability to enhance both efficacy and tolerability in ADC-based regimens, supporting its positioning...

Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 program Completed public offering of equity securities for gross proceeds of $431.3 million Cash, cash equivalents, and short-term investments of $82 million as of March 31, 2026, not including the subsequent financingWAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026 financial results. “The positive Phase 2 LOTUS trial results of abdakibart in HS, which demonstrated a deep and consistent clinical response across both HiSCR75...

Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026. “During the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “We work towards restarting enrollment in the amended VERSATILE-003 Phase 3 trial. With regards to PDS01ADC, we have completed enrollment in the metastatic colorectal cancer trial, and the advanced castration resistant prostate cancer trial continues to recruit well”. Dr....

Q1-2026 Revenue of $45.2 Million, up 3% Year-over-Year; Adjusted EBITDA of $11.6 Million, representing a Robust 26% Margin of Revenues; Net Income of $4.1 Million, up 4% Year-over-Year Underlying Demand for the Company’s Products Continues to Increase, Supporting the Company’s Expectation for a Significantly Stronger Remainder of 2026 Company Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Annual Double-Digit Organic Profitable Growth Q1-2026 Results Impacted by Temporary Shipment Delay of a Single Order, Subsequently Delivered during April  Company Continues to Evaluate Near-Term Business Development and M&A Transactions to Further Enhance Long-Term Profitable Growth Conference Call and Live Webcast Today at 8:30am ETREHOVOT, Israel, and HOBOKEN,...

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc., (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal first quarter ended April 4, 2026. Highlights1Q 2026 revenues of $839.2 million Gross margin was 21.0% 1Q 2026 GAAP EPS of $0.05 1Q 2026 book-to-bill of 1.34 with book-to-bill of 1.47 for semiconductors and 1.23 for passive components Backlog at quarter end was 5.7 months“Vishay’s first quarter financial results demonstrate that the Vishay 3.0 strategy is working. As a result of the investments we made to expand capacity of high-growth, high-margin products, Vishay is reliably scaling with our customers. Our top priority going forward is to increase backlog turns to ensure we maintain competitive...

RAPALA VMC CORPORATION, Company release, May 13, 2026 at 2:15 p.m. EEST January-March (Q1) in briefNet sales were 69.5 MEUR, up 6% from previous year (65.3).With comparable exchange rates sales were 13% up from previous year. Comparable operating profit* was 7.8 MEUR (5.6). Cash flow from operations was -3.8 MEUR (-9.3). Inventories were 82.5 MEUR (84.9). Short-term outlook: The Group expects 2026 full year comparable operating profit* to increase from 2025.President and CEO Cyrille Viellard: “A positive start to 2026 with 13% sales growth at comparable exchange rates, supported by exciting new product introductions and efficient supply chain execution, enabled an encouraging performance despite continued global market uncertainty. I would like to extend a sincere thank you to the entire Rapala VMC team for their dedication to deliver...